Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 1001-1006

  Lee, Jung Goo ^a,b   Cho, Hye Yeon ^a   Park, Sung Woo ^a   Seo, Mi Kyoung ^b   Kim, Young Hoon ^a,b  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Atypical antipsychotics; BDNF gene promoter activity; Neuroprotective effect; Olanzapine; Protein kinase

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; LUCIFERASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NEUROTROPHIC FACTOR; OLANZAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; WORTMANNIN; ACTIVATING TRANSCRIPTION FACTOR 2; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3; NEUROLEPTIC AGENT;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROPROTECTION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; PROMOTER REGION; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 2; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 77955050185     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.05.013     Document Type: Article

References (61)

1. Aid T., Kazantseva A., Piirsoo M., Palm K., Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007, 85:525-535.
2. Bai O., Wei Z., Bowen R., Keegan D., Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 2002, 69:278-283.
3. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71:127-131.
4. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28:166-172.
5. Beaulieu J.M., Marion S., Rodriguiz R.M., Medvedev I.O., Sotnikova T.D., Ghisi V., et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008, 132:125-136.
6. Bimonte H.A., Nelson M.E., Granholm A.C. Age-related deficits as working memory load increases: relationships with growth factors. Neurobiol Aging 2003, 24:37-48.
7. Blanquet P.R., Mariani J., Derer P. A calcium/calmodulin kinase pathway connects brain-derived neurotrophic factor to the cyclic AMP-responsive transcription factor in the rat hippocampus. Neuroscience 2003, 118:477-490.
8. Bramham C.R., Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005, 76:99-125.
9. Cahn W., Hulshoff Pol H.E., Lems E.B., van Haren N.E., Schnack H.G., van der Linden J.A., et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002, 59:1002-1010.
10. Chen M.J., Russo-Neustadt A.A. Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res Mol Brain Res 2005, 135:181-193.
11. Chen H.X., Otmakhov N., Strack S., Colbran R.J., Lisman J.E. Is persistent activity of calcium/calmodulin-dependent kinase required for the maintenance of LTP?. J Neurophysiol 2001, 85:1368-1376.
12. Crowder R.J., Freeman R.S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 2000, 275:34266-34271.
13. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-682.
14. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005, 30:765-774.
15. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
16. Du J., Feng L., Yang F., Lu B. Activity- and Ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J Cell Biol 2000, 150:1423-1434.
17. Durany N., Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 2004, 19:326-337.
18. Elgersma Y., Sweatt J.D., Giese K.P. Mouse genetic approaches to investigating calcium/calmodulin-dependent protein kinase II function in plasticity and cognition. J Neurosci 2004, 24:8410-8415.
19. Espada S., Rojo A.L., Salinas M., Cuadrado A. The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neurotransmission with neuroprotection. J Neurochem 2009, 110:1107-1119.
20. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 2000, 97:11960-11965.
21. Fukunaga K., Miyamoto E. A working model of CaM kinase II activity in hippocampal long-term potentiation and memory. Neurosci Res 2000, 38:3-17.
22. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007, 420:45-48.
23. Giachino C., De Marchis S., Giampietro C., Parlato R., Perroteau I., SchU{double acute}z G., et al. cAMP response element-binding protein regulates differentiation and survival of newborn neurons in the olfactory bulb. J Neurosci 2005, 25:10105-10118.
24. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122.
25. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001, 78:1219-1232.
26. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
27. Hammonds M.D., Shim S.S. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 2009, 105:113-119.
28. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Lee C.U., Ciszewski A.A., et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003, 160:156-164.
29. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64:633-647.
30. Kim N.R., Park S.W., Lee J.G., Kim Y.H. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:633-642.
31. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214-219.
32. Kurosawa S., Hashimoto E., Ukai W., Toki S., Saito S., Saito T. Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J Neural Transm 2007, 114:1121-1128.
33. Li M., Wang X., Meintzer M.K., Laessig T., Birnbaum M.J., Heidenreich K.A. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 2000, 20:9356-9363.
34. Liang M.H., Chuang D.M. Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 2006, 281:30479-30484.
35. Lieberman J.A., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001, 49:487-499.
36. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S. HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005, 62:361-370.
37. Lieberman J.A., Perkins D.O., Jarskog L.F. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr 2007, 12:1-13.
38. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous. Neuron 2002, 35:605-623.
39. Lu X.H., Bradley R.J., Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 2004, 1011:58-68.
40. Luo C., Xu H., Li X.M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005, 1063:32-39.
41. Mai L., Jope R.S., Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 2002, 82:75-83.
42. McAllister A.K., Lo D.C., Katz L.C. Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 1995, 15:791-803.
43. Novak G., Seeman P., Tallerico T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse 2006, 59:61-68.
44. Parikh V., Khan M.M., Mahadik S.P. Olanzapine counteracts reduction of brain derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004, 356:135-139.
45. Park S.W., Lee S.K., Kim J.M., Yoon J.S., Kim Y.H. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett 2006, 402:25-29.
46. Park S.W., Lee C.H., Lee J.G., Lee S.J., Kim N.R., Choi S.M., et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA expression in the hippocampus and neocortex of rats. J Psychiatr Res 2009, 43:274-281.
47. Park S.W., Lee J.G., Ha E.K., Choi S.M., Cho H.Y., Seo M.K., et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 2009, 19:356-362.
48. Pencea V., Bingaman K.D., Wiegand S.J., Luskin M.B. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001, 21:6706-6717.
49. Perkinton M.S., Sihra T.S., Williams R.J. Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons. J Neurosci 1999, 19:5861-5874.
50. Shieh P.B., Ghosh A. Molecular mechanisms underlying activity-dependent regulation of BDNF expression. J Neurobiol 1999, 41:127-134.
51. Shieh P.B., Hu S.C., Bobb K., Timmusk T., Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 1998, 20:727-740.
52. Tan Y.L., Zhou D.F., Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2005, 74:260-270.
53. Tao X., Finkbeiner S., Arnold D.B., Shaywitz A.J., Greenberg M.E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998, 20:709-726.
54. Turalba A.V., Leite-Morris K.A., Kaplan G.B. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci Lett 2004, 357:53-57.
55. Wakada C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002, 69:72-79.
56. Wang H.D., Dunnavant F.D., Jarman T., Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004, 29:1230-1238.
57. Wei Z., Bai O., Richardson J.S., Mousseau D.D., Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003, 73:364-368.
58. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J Neurosci Res 2003, 74:942-947.
59. Wilson J., Lin H., Fu D., Javitch J.A., Strange P.G. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J Neurochem 2001, 77:493-504.
60. Yan Z., Feng J., Fienberg A.A., Greengard P. D(2) dopamine receptors induce mitogen activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci U S A 1999, 96:11607-11612.
61. Yulug B., Yildiz A., Hudaoglu O., Kilic E., Cam E., Schabitz W.R. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull 2006, 1:296-300.